Drug profile

The FDA adverse-event record for Chlorhexidine + Ophytrium

149 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Chlorhexidine + Ophytrium. See the species affected, top reactions, and outcomes below.

149
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
53
Application site erythema - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
149
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

ChlorhexidineOphytrium

Administration Routes

TopicalUnknown

Species Affected

Dog 134
Cat 10
Human 5

Most Affected Breeds

Crossbred Canine/dog 30
Dog (unknown) 16
Retriever - Labrador 9
Unknown 8
Pit Bull 7
Maltese 7
Domestic Shorthair 6
Mixed (Dog) 5
Shih Tzu 4
Terrier - Boston 4

Most Reported Reactions

Application site erythema 53
Application site pain 18
Application site pruritus 16
Application site inflammation 16
Application site reddening 14
Lack of efficacy - NOS 10
Vocalisation 9
Application site irritation 9
Licking at application site 7
Application site scab 6
Lethargy (see also Central nervous system depression in Neurological) 6
Application site crust 6

Outcome Breakdown

Ongoing
69 (46.3%)
Recovered/Normal
59 (39.6%)
Outcome Unknown
21 (14.1%)

Chlorhexidine + Ophytrium Adverse Event Insights

149 reports name Chlorhexidine + Ophytrium; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredients: Chlorhexidine, Ophytrium. Administration routes: Topical, Unknown.

By species: Dog (134 reports), Cat (10 reports), Human (5 reports). By breed: Crossbred Canine/dog (30), Dog (unknown) (16), Retriever - Labrador (9).

Leading clinical signs: Application site erythema (53), Application site pain (18), Application site pruritus (16), Application site inflammation (16). Outcome, 149 coded reports: Ongoing leads at 46.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.